COMMUNIQUÉ DE PRESSE publié le 16/05/2024 à 16:00, il y a 1 année 11 mois Adolore BioTherapeutics Announces Publication Demonstrating Carbonic Anhydrase-8 Gene Therapy (rdHSV-CA8) Decreased Pain-Sensing Neuronal Excitability by Activating Kv7 Voltage-Gated Potassium Channels Adolore BioTherapeutics announces groundbreaking findings in gene therapy for chronic pain treatment, highlighting the value of non-opioid analgesics and progress with IND-enabling studies Adolore BioTherapeutics Chronic Pain Gene Therapy Non-opioid Analgesics IND-enabling Studies
BRÈVE publiée le 04/03/2024 à 16:05, il y a 2 années 2 mois Adolore BioTherapeutics obtient un brevet américain pour la thérapie génique CA8* dans le traitement de la douleur chronique Adolore BioTherapeutics Thérapie Génique Traitement De La Douleur Chronique Solutions Sans Opioïdes Délivrance De Brevet
BRÈVE publiée le 04/03/2024 à 16:05, il y a 2 années 2 mois Adolore BioTherapeutics Secures U.S. Patent for CA8* Gene Therapy in Chronic Pain Treatment Adolore BioTherapeutics Gene Therapy Chronic Pain Treatment Opioid-Free Solutions Patent Issuance
COMMUNIQUÉ DE PRESSE publié le 04/03/2024 à 16:00, il y a 2 années 2 mois Adolore BioTherapeutics Announces Issuance of First U.S. Patent Covering CA8* Gene Therapies to Treat Chronic Pain Adolore BioTherapeutics licenses patent and CA8* gene therapy technology from the University of Miami for opioid-free chronic pain treatment. Company progresses toward clinical testing and commercialization University Of Miami Adolore BioTherapeutics Chronic Pain Opioid-free Gene Therapy
COMMUNIQUÉ DE PRESSE publié le 30/01/2024 à 16:00, il y a 2 années 3 mois Adolore BioTherapeutics to Present at the 5th Annual National Institutes of Health (NIH) HEAL Initiative Scientific Meeting Adolore BioTherapeutics will present at the 5th Annual NIH HEAL Initiative Scientific Meeting regarding the gene therapy program for chronic pain associated with knee osteoarthritis. The program is supported by NIH/NINDS HEAL UH3 Award Adolore BioTherapeutics Chronic Pain NIH HEAL Initiative Gene Therapy Osteoarthritis
COMMUNIQUÉ DE PRESSE publié le 05/12/2023 à 16:30, il y a 2 années 5 mois Adolore BioTherapeutics Presents Promising Preclinical Data Supporting Its Innovative Gene Therapy to Treat Chronic Pain Adolore BioTherapeutics presented preclinical data supporting its innovative CA8* gene therapy as a long-acting local analgesic for chronic osteoarthritis knee pain management, aiming to replace opioids Adolore BioTherapeutics CA8* Gene Therapy Chronic Pain Opioid-free Preclinical Data
COMMUNIQUÉ DE PRESSE publié le 11/10/2023 à 16:00, il y a 2 années 6 mois Adolore BioTherapeutics to Participate at the Virtual Investor Ask the CEO Conference
COMMUNIQUÉ DE PRESSE publié le 03/10/2023 à 15:15, il y a 2 années 7 mois NIN/NINDS HEAL Program Grants Prestigious UH3 Award to the University of Miami, Principal Investigator Roy C. Levitt M.D, to Fund Clinical Development of Adolore BioTherapeutics’ Gene Therapy Program for the Treatment of Chronic Osteoarthritis Knee Pain
Publié le 07/05/2026 à 19:15, il y a 1 jour 23 heures 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Publié le 07/05/2026 à 19:15, il y a 1 jour 23 heures Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Publié le 07/05/2026 à 19:06, il y a 1 jour 23 heures Disclosure of Share Capital and Voting Rights as of April 30, 2026
Publié le 07/05/2026 à 19:06, il y a 1 jour 23 heures Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Publié le 07/05/2026 à 19:00, il y a 1 jour 23 heures ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Publié le 09/05/2026 à 01:30, il y a 16 heures 53 minutes Star Copper Announces Agreement with Zimtu Capital Corp.
Publié le 09/05/2026 à 00:00, il y a 18 heures 23 minutes Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Publié le 08/05/2026 à 20:38, il y a 21 heures 45 minutes EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Publié le 08/05/2026 à 19:12, il y a 23 heures 10 minutes EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Publié le 08/05/2026 à 19:02, il y a 23 heures 21 minutes Metall Zug – Annual General Meeting of Shareholders approves all proposals